Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad A G
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Neuropsychopharmacology. 2001 Nov;25(5):642-50. doi: 10.1016/S0893-133X(01)00263-9.
Approximately one third of schizophrenic patients treated with neuroleptic drugs experience unpleasant subjective responses, that are collectively known as neuroleptic dysphoria. Experimental research in animals indicates that drug induced dopaminergic blockade in mesolimbic circuits, especially the nucleus accumbens, leads to impaired pleasure responsivity and dysphoria. The present study tested this putative mechanism in drug-free schizophrenic patients (n = 12), through inducing dysphoric responses with alphamethyl paratyrosine (AMPT) and simultaneously quantifying their baseline striatal dopmine (D(2)) function with (123)IBZM-SPECT imaging. Results showed a wide variability in the occurrence and severity of dysphoric responses, clearly distinguishing a dysphoric group from non-dysphoric responders. Severity of dysphoric responses, measured by standardized rating scales, correlated inversely with changes in D(2) receptor binding ratios (r = +0.82, p <.01). These results support the notion that striatal dopaminergic activity is not uniformly elevated in all schizophrenic patients, and the sub-group of individuals with lower baseline dopamine function are at an increased risk for dysphoric responses during antipsychotic therapy with dopaminergic blocking drugs.
接受抗精神病药物治疗的精神分裂症患者中,约有三分之一会出现不愉快的主观反应,这些反应统称为抗精神病药烦躁症。对动物的实验研究表明,药物诱导的中脑边缘回路,尤其是伏隔核中的多巴胺能阻滞,会导致愉悦反应性受损和烦躁不安。本研究通过用α-甲基对酪氨酸(AMPT)诱导烦躁反应,并同时用(123)IBZM-SPECT成像定量无药物治疗的精神分裂症患者(n = 12)的基线纹状体多巴胺(D(2))功能,来检验这一假定机制。结果显示,烦躁反应的发生和严重程度存在很大差异,明显区分出烦躁组和无烦躁反应组。通过标准化评分量表测量的烦躁反应严重程度与D(2)受体结合率的变化呈负相关(r = +0.82,p <.01)。这些结果支持这样一种观点,即并非所有精神分裂症患者的纹状体多巴胺能活性都会一致升高,基线多巴胺功能较低的个体亚组在使用多巴胺能阻断药物进行抗精神病治疗期间出现烦躁反应的风险增加。